Filing Details
- Accession Number:
- 0000925421-20-000254
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-17 17:47:16
- Reporting Period:
- 2020-06-15
- Accepted Time:
- 2020-06-17 17:47:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1563577 | Galera Therapeutics Inc. | GRTX | Pharmaceutical Preparations (2834) | V8 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1114448 | Ag Novartis | Lichtstrasse 35, Ch-4056 Basel V8 CH-4056 | No | No | Yes | No | |
| 1297709 | Ltd Bioventures Novartis | Forum 1 - 1.32, Lichtstrasse 35, Ch-4056 Basel V8 CH-4056 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-06-15 | 6,164 | $9.05 | 3,483,395 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-16 | 8,600 | $9.30 | 3,474,795 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-17 | 4,622 | $9.27 | 3,470,173 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.10. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $9.07 to $9.37. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $9.25 to $9.32. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Billionaire Hedge Funds
